Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Daily News

COVID-19: TCTMD’s Dispatch for February Week 4

Todd Neale

February 21, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

Shelley Wood

November 17, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

Shelley Wood

July 20, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

Advertisement

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

ATTRibute-CM Top-Line Results Favorable for Acoramidis

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

COVID-19: TCTMD’s Dispatch for February Week 4

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content